Navigation Links
BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
Date:8/27/2013

JERUSALEM, Aug. 27, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2013 Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The BioLineRx presentation is scheduled to start at 10:55 a.m. EDT on Wednesday, September 11, 2013. A live audio webcast of the presentation will be available online at the investor page of the Company's website. An archive of the event will also be available for 30 days following the conference, for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact their Stifel Nicolaus representative.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contact:
KCSA Strategic Communications
Garth Russell / Todd Fromer
+1 212-896-1250 / +1 212-896-1250
grussell@kcsa.com / tfromer@kcsa.com

or

Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il


'/>"/>
SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
2. BioLineRx Reports Second Quarter 2013 Results
3. BioLineRx Appoints B. J. Bormann to Board of Directors
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
10. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
11. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017  Delcath Systems, Inc. (NASDAQ: ... the treatment of primary and metastatic liver cancers, today ... CRNP, President and Chief Executive Officer of Delcath will ... Capital Markets, Thirteenth Annual Investor Conference at the Boca ... Florida , on Tuesday, January 31, 2017 at ...
(Date:1/23/2017)... , January 23, 2017 ... (r enal) y el riesgo ... de a pabetalone    Resverlogix Corp. ... resultados preliminares de un ensayo en fase 1 con ... de riñón (renal) severa. Los datos demostraron unos resultados ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to reach ... worldwide is anticipated to drive the market growth in the coming years. Increasing ... in the recent years. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... ... ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of dry ... new water infrastructure a number one priority. “As we usher in a new national ... become a top priority of our new political change agents.” Kleyne pointed out that ...
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO has ... Chemistry by Applying Simple PAT Tools . , Crystallization is a ... the desired product. Chemists now spend more time developing better intermediate and ...
(Date:1/23/2017)... , ... January 23, 2017 , ... "ProRandom is a set of camera tools that ... dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... two layers of text with video footage. ProRandom works by using a virtual camera ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):